Sam Eldabe1, Katja Burger2, Heinrich Moser2, Daniel Klase3, Stefan Schu4, Anders Wahlstedt5, Bernard Vanderick6, Eric Francois6, Jeffery Kramer7,8, Jeyakumar Subbaroyan7. 1. The James Cook University Hospital, Middlesbrough, UK. 2. Rijnland Ziekenhuis, Leiderdorp, The Netherlands. 3. NC Praxis Rothenbaum, Hamburg, Germany. 4. University of Dusseldorf, Dusseldorf, Germany. 5. Akademiska sjukhuset, Uppsala, Sweden. 6. Clinique et Maternité Sainte-Elisabeth, Namur, Belgium. 7. Spinal Modulation, Inc., Menlo Park, CA, USA. 8. College of Medicine, University of Illinois, Peoria, IL, USA.
Abstract
OBJECTIVES: Phantom limb pain (PLP) is a neuropathic condition in which pain is perceived as arising from an amputated limb. PLP is distinct from, although associated with, pain in the residual limb and nonpainful phantom sensations of the missing limb. Its treatment is extremely challenging; pharmaceutical options, while commonly employed, may be insufficient or intolerable. Neuromodulatory interventions such as spinal cord stimulation have generated mixed results and may be limited by poor somatotopic specificity. It was theorized that dorsal root ganglion (DRG) neuromodulation may be more effective. MATERIALS AND METHODS: Patients trialed a DRG neurostimulation system for their PLP and were subsequently implanted if results were positive. Retrospective chart review was completed, including pain ratings on a 100-mm visual analogue scale (VAS) and patient-reported outcomes. RESULTS: Across eight patients, the average baseline pain rating was 85.5 mm. At follow-up (mean of 14.4 months), pain was rated at 43.5 mm. Subjective ratings of quality of life and functional capacity improved. Some patients reduced or eliminated pain medications. Patients reported precise concordance of the paresthesia with painful regions, including in their phantom limbs; in one case, stimulation eliminated PLP as well as nonpainful phantom sensations. Three patients experienced a diminution of pain relief, despite good initial outcomes. CONCLUSIONS: DRG neuromodulation may be an effective tool in treating this pain etiology. Clinical outcomes in this report support recent converging evidence suggesting that the DRG may be the site of PLP generation and/or maintenance. Further research is warranted to elucidate mechanisms and optimal treatment pathways.
OBJECTIVES: Phantom limb pain (PLP) is a neuropathic condition in which pain is perceived as arising from an amputated limb. PLP is distinct from, although associated with, pain in the residual limb and nonpainful phantom sensations of the missing limb. Its treatment is extremely challenging; pharmaceutical options, while commonly employed, may be insufficient or intolerable. Neuromodulatory interventions such as spinal cord stimulation have generated mixed results and may be limited by poor somatotopic specificity. It was theorized that dorsal root ganglion (DRG) neuromodulation may be more effective. MATERIALS AND METHODS: Patients trialed a DRG neurostimulation system for their PLP and were subsequently implanted if results were positive. Retrospective chart review was completed, including pain ratings on a 100-mm visual analogue scale (VAS) and patient-reported outcomes. RESULTS: Across eight patients, the average baseline pain rating was 85.5 mm. At follow-up (mean of 14.4 months), pain was rated at 43.5 mm. Subjective ratings of quality of life and functional capacity improved. Some patients reduced or eliminated pain medications. Patients reported precise concordance of the paresthesia with painful regions, including in their phantom limbs; in one case, stimulation eliminated PLP as well as nonpainful phantom sensations. Three patients experienced a diminution of pain relief, despite good initial outcomes. CONCLUSIONS: DRG neuromodulation may be an effective tool in treating this pain etiology. Clinical outcomes in this report support recent converging evidence suggesting that the DRG may be the site of PLP generation and/or maintenance. Further research is warranted to elucidate mechanisms and optimal treatment pathways.
Authors: Kassondra L Collins; Hannah G Russell; Patrick J Schumacher; Katherine E Robinson-Freeman; Ellen C O'Conor; Kyla D Gibney; Olivia Yambem; Robert W Dykes; Robert S Waters; Jack W Tsao Journal: J Clin Invest Date: 2018-06-01 Impact factor: 14.808
Authors: Ashley N Dalrymple; Jordyn E Ting; Rohit Bose; James K Trevathan; Stephan Nieuwoudt; Scott F Lempka; Manfred Franke; Kip A Ludwig; Andrew J Shoffstall; Lee E Fisher; Douglas J Weber Journal: J Neural Eng Date: 2021-11-04 Impact factor: 5.379
Authors: Dongman Chao; Christina M Mecca; Guoliang Yu; Ian Segel; Michael S Gold; Quinn H Hogan; Bin Pan Journal: Pain Date: 2021-12-01 Impact factor: 6.961